Clinical Trial

CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer

Investigator

Shailender Bhatia, MD

Complete title:

A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH AN INTRAVENOUS PD-1-BLOCKING ANTIBODY IN SUBJECTS WITH SELECTED TYPES OF ADVANCED OR METASTATIC CANCER

Trial phase:

Phase II

Study ID:

NCT04916002

Local study ID:

RG1121656

Summary:

CMP-001-009 is a Phase 2 study of intratumoral CMP-001 in combination with an intravenous PD-1-blocking antibody administered to participants with certain types of advanced or metatastic cancer. The primary objective of the study is to determine the Investigator-assessed confirmed objective response with CMP-001 in combination with a programmed cell death protein (PD-1)-blocking antibody in subjects with certain types of advanced or metatastic cancer. The secondary objectives are to: •To evaluate the safety and tolerability of CMP-001 administered by intratumoral (IT) injection in combination with a PD-1-blocking antibody in study subjects. •To evaluate the efficacy of CMP-001 in combination with a PD-1-blocking antibody in study subjects. Participants will continue to receive treatment of CMP-001 in combination with a PD-1-blocking antibody according to the treatment schedule until a reason for treatment discontinuation is reached.

Trial keywords:

Neoplasms, Advanced Malignant, Metastatic Solid Tumors

View Trial at NIH

Enrollment status:

Recruiting

Trial eligibility

** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.

Learn more

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Patient Guide to Clinical Trials

For more information about Fred Hutch and to schedule an appointment.

Request an Appointment

Back To: Clinical Trials Homepage